Australië - Engels - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; hyprolose; iron oxide yellow; maize starch; microcrystalline cellulose; lactose monohydrate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: iron oxide red; maize starch; microcrystalline cellulose; lactose monohydrate; hyprolose; magnesium stearate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; hyprolose; lactose monohydrate; microcrystalline cellulose; indigo carmine aluminium lake - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole 20mg;   - orodispersible tablet - 20 mg - active: aripiprazole 20mg   excipient: acesulfame potassium aspartame calcium silicate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose tartaric acid vanilla flavour 27243 xylitol

Verenigde Staten - Engels - NLM (National Library of Medicine)

stat rx usa llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . monotherapy abilify is indicated for the acute and maintenance treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). maintenance efficacy was demonstrated in a monotherapy trial in adults and can be extrapolated to pediatric patients (10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy abilify is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in one 6-week adjunctive trial in adults and can be e

Verenigde Staten - Engels - NLM (National Library of Medicine)

rebel distributors corp. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . monotherapy abilify is indicated for the acute and maintenance treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). maintenance efficacy was demonstrated in a monotherapy trial in adults and can be extrapolated to pediatric patients (10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy abilify is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in one 6-week adjunctive trial in adults and can be e

Verenigde Staten - Engels - NLM (National Library of Medicine)

carilion materials management - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: abilify injection is indicated for the treatment of: abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2) ] . pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abilify during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including abilify) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. adequate and well controlled studies with abilify have not been conducted in pregnant women. animal reproduction studies were con

Verenigde Staten - Engels - NLM (National Library of Medicine)

carilion materials management - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - abilify oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: abilify injection is indicated for the treatment of: abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2) ] . pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abilify during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including abilify) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. adequate and well controlled studies with abilify have not been conducted in pregnant women. animal reproduction studies were con

Verenigde Staten - Engels - NLM (National Library of Medicine)

carilion materials management - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - abilify oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: abilify injection is indicated for the treatment of: abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2) ] . pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abilify during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including abilify) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. adequate and well controlled studies with abilify have not been conducted in pregnant women. animal reproduction studies were con

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole 10mg;   - tablet - 10 mg - active: aripiprazole 10mg   excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - abilify is indicated of the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.